No Data
No Data
Salubris Bio (688163.SH) plans to distribute a dividend of 0.12 yuan per share on September 12th.
Sailun Biology (688163.SH) announced that the company plans to distribute interim dividends for the first half of 2024: cash dividends per share...
Syren Biotech: 2024 Semi-Annual Report
Syren Biotech: 2024 Semi-Annual Report Summary
Sailun Biology (688163.SH) released its performance for the first half of the year, with a net income of 32.3078 million yuan, a year-on-year growth of 20.06%.
Sailun Bio (688163.SH) released its semi-annual report for 2024, reporting a revenue of 9...
Selon Biotechnology (SH 688163): Some shareholders collectively increased their shareholding by 0.29% in the company.
On August 15th, Gelunhui reported that Celanese Biomedical (688163.SH) received a notice from the shareholding entity on August 15th, 2024 regarding the completion of the shareholding. From February 26th, 2024 to August 15th, 2024, the shareholding entity accumulated 318,923 shares of the company through the Shanghai Stock Exchange trading system in a centralized bidding manner, accounting for approximately 0.29% of the total share capital of the company. The total amount of the shareholding is RMB 4,543,506.43 (excluding transaction costs), which exceeds the lower limit of the shareholding plan. The shareholding plan has been fully implemented.
Sailun Biology (688163.SH) has not yet reserved technology in synthetic biology.
On August 7th, Gelon Hui reported that Celon Pharma (688163.SH) stated on its interactive platform that the company has not yet made any technological reserves in the field of synthetic biology.
No Data
No Data